Marcelo Bigal Biography and Net Worth

Director of Pacira BioSciences

Dr. Bigal is the President and Chief Executive Officer of Ventus Therapeutics and brings extensive experience in neurology to the Pacira Board of Directors. He has published over 330 peer-reviewed papers in the field of neurology, as well as five books. He has been recognized by the American Academy of Neurology with the Harold G. Wolff Award for excellence in research in neurology.

Dr. Bigal has over 15 years of pharmaceutical experience spanning research and development; medical affairs; and scientific affairs. Prior to Ventus, he was CMO and Head of Specialty Research and Development at Teva Pharmaceuticals, as well as CMO at Labrys Biologicals, leading the team that developed fremanezumab (AJOVY^®) for several forms of migraine, as well as deutetrabenazine (AUSTEDO^®) for the treatment of Huntington’s disease and tardive dyskinesia, as well as other medicines in neurology, psychiatry, pain, and respiratory diseases approved in the US, Canada, and EU.

Prior to his work in the pharmaceutical industry, Dr. Bigal was a faculty member at the Albert Einstein College of Medicine, Department of Neurology, as well as the Director of Research at New England Center for Headache and Director of Research at Montefiore Headache Center.

What is Marcelo Bigal's net worth?: The estimated net worth of Marcelo Bigal is at least $252,434.38 as of August 16th, 2024. Dr. Bigal owns 10,142 shares of Pacira BioSciences stock worth more than $252,434 as of April 2nd. This net worth estimate does not reflect any other assets that Dr. Bigal may own. Learn More about Marcelo Bigal's net worth.
How do I contact Marcelo Bigal?: The corporate mailing address for Dr. Bigal and other Pacira BioSciences executives is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. Pacira BioSciences can also be reached via phone at (813) 553-6680 and via email at susan.mesco@pacira.com. Learn More on Marcelo Bigal's contact information.
Has Marcelo Bigal been buying or selling shares of Pacira BioSciences?: Marcelo Bigal has not been actively trading shares of Pacira BioSciences during the last quarter. Most recently, on Friday, August 16th, Marcelo Bigal bought 1,512 shares of Pacira BioSciences stock. The stock was acquired at an average cost of $13.25 per share, with a total value of $20,034.00. Following the completion of the transaction, the director now directly owns 10,142 shares of the company's stock, valued at $134,381.50. Learn More on Marcelo Bigal's trading history.
Who are Pacira BioSciences' active insiders?: Pacira BioSciences' insider roster includes Marcelo Bigal (Director), Mark Froimson (Director), Mark Kronenfeld (Director), Frank Lee (Chief Executive Officer & Director), Donald Manning (Insider), Max Reinhardt (Insider), Charles Reinhart, III (CFO), Lauren Riker (VP), Jonathan Slonin (Chief Medical Officer), David Stack (CEO), Andreas Wicki (Director), Kristen Williams (Insider), Kristen Williams (Chief Administrative Officer & Secretary), and Roy Winston (Insider). Learn More on Pacira BioSciences' active insiders.
Are insiders buying or selling shares of Pacira BioSciences?: In the last twelve months, Pacira BioSciences insiders bought shares 3 times. They purchased a total of 11,176 shares worth more than $136,240.40. In the last twelve months, insiders at the sold shares 10 times. They sold a total of 23,974 shares worth more than $653,601.25. The most recent insider tranaction occured on January, 6th when insider Jonathan Slonin sold 879 shares worth more than $16,173.60. Insiders at Pacira BioSciences own 6.4% of the company. Learn More about insider trades at Pacira BioSciences.
Information on this page was last updated on 1/6/2025.

Marcelo Bigal Insider Trading History at Pacira BioSciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/16/2024	Buy	1,512	$13.25	$20,034.00	10,142

Marcelo Bigal Buying and Selling Activity at Pacira BioSciences

Pacira BioSciences Company Overview

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Today's Range

Now: $24.89

$23.66

$24.93

50 Day Range

MA: $24.89

$22.04

$27.25

2 Week Range

Now: $24.89

$11.16

$31.67

Volume

452,799 shs

Average Volume

937,086 shs

Market Capitalization

$1.15 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86